Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-arm Exploratory Clinical Study of Conversion Treatment of Hepatic Arterial Infusion Chemotherapy Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

Next Previous
Trial Profile

A Single-arm Exploratory Clinical Study of Conversion Treatment of Hepatic Arterial Infusion Chemotherapy Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Rivoceranib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use

Most Recent Events

  • 07 May 2025 Results (n=19, Median follow-up was 14.9 months) investigating the efficacy and safety of HAIC combined with camrelizumab and apatinib as conversion therapy for uHCC published in the BMC Cancer.
  • 12 Aug 2023 Planned End Date changed from 30 Mar 2024 to 31 Dec 2024.
  • 12 Aug 2023 Planned primary completion date changed from 31 Dec 2023 to 30 Jun 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top